Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThe relationship between weight loss injections and mental health is more layered than most people expect. GLP-1 medicines like Mounjaro and Wegovy can ease the psychological burden that often accompanies living with obesity, yet they also carry monitoring requirements around mood — something every prescriber should discuss with you before starting. These are prescription-only medicines, and clinical assessment takes both physical and mental health into account. The decision about whether to start is a personal one, and it deserves a patient, honest conversation.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
A question our prescribers hear most weeks goes something like: "I've struggled with anxiety and a difficult relationship with food for years, is this kind of medication right for me?" It's a fair thing to ask. Weight and mental health are tangled in ways that run deeper than the clinical checklist.
Living with obesity is associated with higher rates of depression, anxiety, and low self-esteem, not because weight causes those conditions in a simple mechanical sense, but because the social, physical, and hormonal effects of excess weight are real and cumulative. The NHS's overview of obesity notes psychological difficulties as a recognised consequence, not a character flaw. When people consider weight loss injections, they are often already carrying that psychological load.
Understanding what GLP-1 medicines might do for, and occasionally to, your mental health is therefore not a footnote. It's central to the decision. The sections below lay out what the evidence supports, where genuine uncertainty remains, and what a thoughtful clinical assessment should cover.
Across clinical trials, participants who lost significant weight reported improvements in quality of life, self-reported mood, and confidence, and this pattern holds for GLP-1 treatments. The SURMOUNT-1 trial, involving thousands of adults treated with tirzepatide, collected patient-reported outcome data alongside physical measurements, and the picture was broadly positive. People ate with less guilt, moved more freely, and described feeling more like themselves.
There is also early research interest in whether GLP-1 receptors in the brain play a direct role in mood regulation, separate from the effects of weight change itself. The science here is preliminary and should be described carefully: it is intriguing, not settled. What is more established is the indirect pathway. Chronic pain from joint problems eases. Sleep improves as sleep apnoea symptoms reduce. Energy lifts. Those changes have real consequences for mental wellbeing. If you want a broader picture of documented health benefits associated with weight loss injections, there is more detail on that page.
None of this amounts to a guarantee of improved mood. Psychological responses to significant body change are not uniform. Some people feel confronted by shifts in identity or relationship dynamics as their weight changes. Those responses are normal and worth being prepared for.
In 2023 and into 2024, regulatory bodies in Europe and the United States reviewed spontaneous reports of suicidal thoughts associated with GLP-1 medicines. The MHRA engaged in that review. The conclusion, reflected in the current prescribing information, was that a causal relationship has not been established, the signal in adverse event reports did not survive careful adjustment for the background rate of depression and self-harm in people living with obesity. However, the absence of confirmed causation is not the same as absence of concern, and the precautionary monitoring requirement remains.
Prescribers are expected to ask about mental health history before initiating treatment and at each review. If you have a history of severe depression, recent suicidal ideation, or are currently on medication for mood conditions, that is part of the clinical conversation, not a reason to be turned away. It shapes how the prescriber monitors you and how frequently they want to hear from you. The MHRA's Drug Safety Update index is the definitive place to track any regulatory position changes on this topic.
Separately, the early weeks on a new dose can bring tiredness, nausea, and disrupted appetite, all of which can make anyone feel flat. That is worth knowing in advance so you can tell the difference between a temporary adjustment response and something that needs clinical attention.
The right framework for this decision is not "does my mental health history disqualify me" but rather "how do I and my prescriber manage this together." Existing anxiety or depression, a history of disordered eating, or current use of psychiatric medication are each relevant disclosures. They allow your prescriber to personalise the plan: perhaps starting at the lowest dose and extending the titration period, scheduling more frequent check-ins, or coordinating with your GP.
Disordered eating deserves a specific mention. GLP-1 medicines dramatically reduce appetite, which can be freeing for some people and disorienting for others. If your relationship with food has previously involved restriction, bingeing, or purging, discuss that openly. Beat, the UK's eating disorder charity, notes that weight-focused treatment can sometimes intersect uncomfortably with disordered patterns, not inevitably, but it is something a prescriber should factor in.
For people who are broadly well and simply want to understand the landscape before starting, the broader question of how healthy these injections are covers the full risk-benefit picture. If you have specific concerns about health concerns associated with weight loss injections, that page goes into more detail. Anyone who has already done their research and wants to explore whether treatment is suitable for them is welcome to speak to our prescribers, a GPhC-registered Independent Prescriber reads every consultation the same day. The assessment covers mental health history as standard, and there is no pressure toward any particular outcome. Sometimes the most useful thing a prescriber can do is help you decide this is not the right moment. If you are weighing up which option to choose, our guide to the healthiest weight loss injections currently available compares the leading medicines on safety and tolerability, and if you are considering a structured programme through a hospital provider, we also have a dedicated page covering weight loss injections offered through Nuffield Health.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.